Αποτελέσματα Αναζήτησης
Most side effects occur while you are actively receiving treatment, but in some cases certain side effects can occur months to years after treatment is complete. Based upon the treatment you received, ask your pharmacist if there are any side effects that you should watch out for in the future.
- Early Stage
Other risk factors for breast cancer include family history...
- Neutropenic Fever
Without proper treatment, neutropenic fever can cause...
- Early Stage
11 Απρ 2024 · A review in 2015 reported that sequential Adriamycin-cyclophosphamide therapy followed by paclitaxel or docetaxel appears to be the most effective treatment regimen of early-stage breast cancer regardless of hormone status. What are the side effects of AC for breast cancer?
16 Ιουλ 2018 · If your doctor has recommended the chemo regime AC + T for breast cancer, here's what you should know about how it works and the potential side effects.
8 Οκτ 2014 · Although 90% of women are diagnosed with early breast cancer, prospective studies have shown breast cancer–specific mortality rates exceeding 50% at 30-year follow-up in women treated with surgery alone. 3 Although local therapies can eradicate disease in the breast and axilla, early systemic dissemination of microscopic disease often precedes l...
Fertility, pregnancy and lactation Cancer treatment can have harmful effects on fertility and this should be discussed with all patients of reproductive potential prior to commencing treatment. There is a risk of foetal harm in pregnant women.
18 Αυγ 2021 · The regimen was well tolerated; there were few events of cardiotoxicity, 21 mostly reversible, and no patient developed secondary hematologic malignancies. 22 Based on outstanding efficacy and limited toxicity seen in this trial, the TH regimen is a reasonable and appealing treatment approach for small, node-negative, HER2-positive BC. 2, 23, 24.
However, in the United States, doxorubicin/cyclophosphamide (AC) is favored over FEC despite no data comparing neoadjuvant AC-THP with AC-TH or TCHP. Here we report outcomes for patients with localized HER2+ breast cancer treated with pertuzumab-containing neoadjuvant regimens and AC-TH.
